Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management.
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management.
复制标题
DOI：
10.2147/ptt.s328575
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Yiu ZZN
中科院分区：
文献类型：
--
作者：
Al-Janabi A;Yiu ZZN
靶向Th 1/Th 17细胞因子的生物制剂彻底改变了银屑病治疗。除了治疗有效性外，重要的是要定义和了解生物治疗的长期风险，以指导治疗选择并尽可能减少患者的这些风险。这篇综述文章总结了来自试验数据、观察性研究和药物警戒登记的现有证据，以探讨生物治疗的关键长期风险，以及如何在临床实践中管理这些风险。
Biologics targeting Th1/Th17 cytokines have revolutionised psoriasis treatment. In addition to treatment effectiveness, it is important to define and understand the long-term risks of biologic therapy in order to guide therapy selection and minimise these risks for patients where possible. This review article summarises available evidence from trial data, observational studies and pharmacovigilance registries to explore key long-term risks of biologic treatment, and how these risks might be managed in clinical practice.